When was Genenta Science founded?

Genenta Science was founded in 2014 and raised its 1st funding round 1 year after it was founded.

Where is Genenta Science located?

Genenta Science is headquartered in Milan, Italy.

How many employees does Genenta Science have?

As of Mar 31, 2026, the latest employee count at Genenta Science is 23.

Is Genenta Science a funded company?

Genenta Science is a funded company, having raised a total of $33.6M across 4 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Mar 05, 2015.

When was the latest funding round of Genenta Science?

Genenta Science's latest funding was a $***** Post IPO round on Mar 19, 2025, with participation from 1 investor.

Where does Genenta Science rank among its competitors?

Genenta Science ranks 304th amongst 3352 active competitors, of which 1142 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Genenta Science, which secured $21.9M in Mar, 2025.

Who are the top competitors of Genenta Science?

Genenta Science's top competitors include Jazz Pharmaceuticals, Moderna and Spark Therapeutics. Among them, Genenta Science secured the most recent funding round in March, 2025.

Genenta Science - 2026 Company Profile, Team, Funding & Competitors

Genenta Science is a public company based in Milan (Italy), founded in 2014 by Pierluigi Paracchi, Bernhard Gentner and Luigi Naldini. It operates as a Developer of lentivirus-based gene and cell therapies for cancer. Genenta Science has raised $33.6M in funding from Qianzhan and Mediobanca. The company has 3352 active competitors, including 1142 funded and 809 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Moderna and Spark Therapeutics.

Company Details

Developer of lentivirus-based gene and cell therapies for cancer. The lead candidateTemferon is a lentivirus-based hematopoietic stem progenitor cell immuno-gene therapy for Glioblastoma, solid tumor, and hematological malignancies. Also, has Tie2-Expressing Monocytes immunotherapies for multiple cancer treatment.

Website: www.genenta.com/
Social

Key Metrics

Founded Year

2014

Location

Milan, Italy

Stage

Public

Total Funding

$33.6M in 4 rounds

Latest Funding Round

Post IPO, Mar 19, 2025, $*****

Investors

Qianzhan & 4 more

Ranked

304^th among 3352 active competitors

Employee Count

23 as on Mar 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3210 more

Exit Details

Public

View Genenta Science's full profile

Genenta Science got listed on Dec 15, 2021.

Click here to take a look at Genenta Science's IPO in detail

Genenta Science has raised a total funding of $33.6M over 4 rounds. Its first funding round was on Mar 05, 2015. Its latest funding round was a Post IPO round on Mar 19, 2025 for $*****. 1 investor participated in its latest round. Genenta Science has 5 institutional investors.

Here is the list of recent funding rounds of Genenta Science:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 19, 2025	8855781	Post IPO	1290718	8054145	7735265	5244849
Sep 11, 2019	6589726	Series C	5078683	8603985	7717492	8157509
Sep 13, 2017	6922958	Series B	9495098	5141635	3319255	4723039

Access funding benchmarks and valuations. Sign up today!

View details of Genenta Science's funding rounds and investors

The founders of Genenta Science are Pierluigi Paracchi, Bernhard Gentner and Luigi Naldini.

Here are the details of Genenta Science's key team members:

Pierluigi Paracchi: Co-Founder Chairman And Chief Executive Officer of Genenta Science.
Bernhard Gentner: Co-Founder of Genenta Science.
Luigi Naldini: Co-Founder of Genenta Science.

View details of Genenta Science's Founder profiles and Board Members

Genenta Science's employee count trend

Genenta Science has 23 employees as of Mar 26. Here is Genenta Science's employee count trend over the years:

Employee count trend for Genenta Science

Uncover Genenta Science's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Genenta Science include Jazz Pharmaceuticals, Moderna and Spark Therapeutics. Here is the list of Top 10 competitors of Genenta Science, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Prospect Venture Partners, Versant Ventures ... & 14 others	82/100
2nd	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, Astrazeneca & 31 others	81/100
3rd	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Wellington & 6 others	76/100
4th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Bezos Expeditions, F-Prime Capital & 17 others	75/100
5th	Kite Pharma 2009, Los Angeles (United States), Acquired	Developer of cancer immunotherapy products using genetic engineering	$97.7M	Alta Partners, Amgen Business Development ... & 10 others	75/100
6th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	74/100
7th	Juno Therapeutics 2013, Seattle (United States), Acquired	Global biopharmaceutical company discovering, developing, and delivering innovative medicines	$317M	RA Capital Management, BB Biotech & 14 others	74/100
8th	Revolution Medicines 2014, Redwood City (United States), Public	Developer of therapies for the treatment of cancer	$326M	Boxer Capital, The Column Group & 12 others	73/100
9th	Advanced Accelerator Applications 2002, Saint Genis Pouilly (France), Acquired	Novartis company, developing molecular nuclear medicine theranostics	$56.1M	Tamburi Investment Partners, Vivo Capital ... & 4 others	73/100
10th	Regeneron Pharmaceuticals 1988, Tarrytown (United States), Public	Developer of antibodies for the treatment of cancer, eye diseases, inflammatory diseases & others	-	BB Biotech, Kaccelerator & 7 others	73/100
304th	Genenta Science 2014, Milan (Italy), Public	Developer of lentivirus-based gene and cell therapies for cancer	$33.6M	Mediobanca, Growth Engine & 3 others	59/100